Michael J. Overman, Greg Yothers, Shannon L. Puhalla, Hanna Kelly Sanoff, Deirdre J. Cohen, Katherine A Guthrie, Patricia A. Ganz, Scott Kopetz, Peter C. Lucas, Charles D. Blanke, Samuel A. Jacobs, Theodore S. Hong, Norman Wolmark, Howard S. Hochster, Thomas J. George, Caio Max Sao Pedro Rocha Lima. "Colorectal cancer metastatic dMMR immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer 9NRG-GI004/SWOG-S1610).." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.4_suppl.tps311